Global pharma major Lupin Limited (Lupin) announced the launch of Bumetanide Injection USP, 1 mg/4 mL (0.25 mg/mL) Single-Dose Vials and 2.5 mg/10 mL (0.25 mg/mL) Multiple-Dose Vials in the United States, after having received an approval from the United Food and Drug Administration (U.S. FDA).

Bumetanide Injection USP, is a generic equivalent of Bumex Injection, 0.25 mg/mL of Validus Pharmaceuticals, indicated for the treatment of edema associated with congestive heart failure, hepatic and renal disease, including the nephrotic syndrome.

Bumetanide Injection USP (RLD Bumex) had an estimated annual sale of USD 20 million in the U.S. (IQVIA MAT September 2024).